Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Legacy Biotechnologies, the joint venture partner of Nuvilex in Reme-Flu, has commenced production of Reme-Flu and expects it to be ready for consumer purchase within the next 30 days.
Subscribe to our email newsletter
Reme-Flu is Legacy Biotechnologies’ 2-part homeopathic flu remedy designed to help treat symptoms of the flu. Initially, Reme-Flu is expected to be offered on the website www.nutralegacy.com.
In addition, as Reme-Flu nears completion, Legacy Biotechnologies will pursue an agreement with a major marketing company to work directly with both sales and marketing of Reme-Flu in the retail sector. Legacy anticipates that a formal marketing agreement will be reached within the next week.
Martin Schmieg, president and CEO of Nuvilex, said that Reme-Flu will be a great asset to help people of all ages overcome symptoms of the flu. The combination of an internet presence coupled with proven marketing methods will create a strong synergy in helping to quickly build sales and brand awareness of Reme-Flu.
Legacy Biotechnologies is an independent, privately-owned firm specializing in research and development of nutriceutical and cosmeceutical formulations.
Nuvilex is a “Green” products company. Its current products include: Cinnergen, which promotes a healthy glucose metabolism; and Cinnechol, designed to help maintain normal cholesterol levels and support normal cardiovascular function.